Increased Collagen Type V α2 (COL5A2) in Colorectal Cancer is Associated with Poor Prognosis and Tumor Progression

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Chen SX, Xu XE, Wang XQ, et al. Identification of colonic fibroblast secretomes reveals secretory factors regulating colon cancer cell proliferation. J Proteomics. 2014;110:155–171. doi:10.1016/j.jprot.2014.07.031
   PubMed Web of Science ®Google Scholar
• Qiao J, Fang CY, Chen SX, et al. Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics. Oncotarget. 2015;6(30):29929–29946. doi:10.18632/oncotarget.4966
   PubMedGoogle Scholar
• Zhang Q, Wang XQ, Wang J, et al. Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients. Oncotarget. 2015;6(17):15095–15110. doi:10.18632/oncotarget.3822
   PubMedGoogle Scholar
• Wang XQ, Tang ZX, Yu D, et al. Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinoma. Oncotarget. 2016;7(8):8823–8838. doi:10.18632/oncotarget.6815
   PubMedGoogle Scholar
• Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. Tumour Biol. 2014;35(4):2871–2882. doi:10.1007/s13277-013-1511-7
   PubMedGoogle Scholar
• JingSong H, Hong G, Yang J, et al. siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration. Oncotarget. 2017;8(2):2585–2593. doi:10.18632/oncotarget.13716
   PubMedGoogle Scholar
• Huang G, Ge G, Izzi V, Greenspan DS. alpha3 Chains of type V collagen regulate breast tumour growth via glypican-1. Nat Commun. 2017;8(1):14351. doi:10.1038/ncomms14351
   PubMed Web of Science ®Google Scholar
• Cortini F, Villa C, Marinelli B, et al. Ehlers-Danlos Syndrome classical type: a novel COL5A2 missense mutation with possible additive effect of a COL5A1 stop-gain mutation in a strongly correlated phenotype. Meta Gene. 2018;18:132–136. doi:10.1016/j.mgene.2018.08.012
   Web of Science ®Google Scholar
• Mak AC, Tang PL, Cleveland C, et al. Brief report: whole-exome sequencing for identification of potential causal variants for diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2016;68(9):2257–2262. doi:10.1002/art.39721
   PubMed Web of Science ®Google Scholar
• Kwong KY, Bloom GC, Yang I, et al. Synchronous global assessment of gene and protein expression in colorectal cancer progression. Genomics. 2005;86(2):142–158. doi:10.1016/j.ygeno.2005.03.012
   PubMed Web of Science ®Google Scholar
• Wu D, Chen K, Bai Y, et al. Screening of diagnostic markers for osteosarcoma. Mol Med Rep. 2014;10(5):2415–2420. doi:10.3892/mmr.2014.2546
   PubMed Web of Science ®Google Scholar
• Januchowski R, Swierczewska M, Sterzynska K, Wojtowicz K, Nowicki M, Zabel M. Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines. J Cancer. 2016;7(10):1295–1310. doi:10.7150/jca.15371
   PubMed Web of Science ®Google Scholar
• Meng XY, Shi MJ, Zeng ZH, et al. The role of COL5A2 in patients with muscle-invasive bladder cancer: a bioinformatics analysis of public datasets involving 787 subjects and 29 cell lines. Front Oncol. 2019;8. doi:10.3389/fonc.2018.00659
   Web of Science ®Google Scholar
• Zou X, Feng B, Dong T, et al. Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis. J Proteomics. 2013;94:473–485. doi:10.1016/j.jprot.2013.10.020
   PubMed Web of Science ®Google Scholar
• Safronetz D, Prescott J, Feldmann F, et al. Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques. Proc Natl Acad Sci U S A. 2014;111(19):7114–7119. doi:10.1073/pnas.1401998111
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Gaedcke J, Grade M, Jung K, et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer. 2010;49(11):1024–1034. doi:10.1002/gcc.20811
   PubMed Web of Science ®Google Scholar
• Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 2010;27(2):83–90. doi:10.1007/s10585-010-9305-4
   PubMed Web of Science ®Google Scholar
• Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 2001;61(7):3124–3130.
   PubMed Web of Science ®Google Scholar
• Skrzypczak M, Goryca K, Rubel T, et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One. 2010;5(10). doi:10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca.
   PubMed Web of Science ®Google Scholar
• Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol. 2007;8(7):R131. doi:10.1186/gb-2007-8-7-r131
   PubMed Web of Science ®Google Scholar
• Yan L, Zhan C, Wang S, Wang S, Guo L. Genetic analysis of radiation-specific biomarkers in sinonasal squamous cell carcinomas. Tumour Biol. 2016;37(9):12001–12009. doi:10.1007/s13277-016-5057-3
   PubMedGoogle Scholar
• Tsukamoto S, Ishikawa T, Iida S, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res. 2011;17(8):2444–2450. doi:10.1158/1078-0432.CCR-10-2884
   PubMed Web of Science ®Google Scholar
• Tsuji S, Midorikawa Y, Takahashi T, et al. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer. 2012;106(1):126–132. doi:10.1038/bjc.2011.505
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kobunai T, Toda E, et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 2006;66(20):9804–9808. doi:10.1158/0008-5472.CAN-06-1163
   PubMed Web of Science ®Google Scholar
• Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138(3):958–968. doi:10.1053/j.gastro.2009.11.005
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26. doi:10.1016/j.devcel.2009.06.016
   PubMed Web of Science ®Google Scholar
• Rammal H, Saby C, Magnien K, et al. Discoidin domain receptors: potential actors and targets in cancer. Front Pharmacol. 2016;7:55.
   PubMed Web of Science ®Google Scholar
• Tao Y, Wang R, Lai Q, et al. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma. Mol Oncol. 2019;13(9):1855–1873. doi:10.1002/1878-0261.12520
   PubMed Web of Science ®Google Scholar
• Jeitany M, Leroy C, Tosti P, et al. Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Mol Med. 2018;10(4). doi:10.15252/emmm.201707918.
   PubMed Web of Science ®Google Scholar
• Chappell WH, Candido S, Abrams SL, et al. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging (Albany NY). 2020;12(11):10194–10210. doi:10.18632/aging.103377
   PubMedGoogle Scholar
• Park AC, Phillips CL, Pfeiffer FM, et al. Homozygosity and heterozygosity for null Col5a2 alleles produce embryonic lethality and a novel classic Ehlers-Danlos syndrome-related phenotype. Am J Pathol. 2015;185(7):2000–2011. doi:10.1016/j.ajpath.2015.03.022
   PubMed Web of Science ®Google Scholar
• Fischer H, Stenling R, Rubio C, Lindblom A. Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis. 2001;22(6):875–878. doi:10.1093/carcin/22.6.875
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Schlegl J, Hahne H, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509(7502):582–587. doi:10.1038/nature13319
   PubMed Web of Science ®Google Scholar
• Albrethsen J, Knol JC, Piersma SR, et al. Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics. 2010;9(5):988. doi:10.1074/mcp.M900546-MCP200
   PubMed Web of Science ®Google Scholar